INVESTORS

Press Releases

Year

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

May 17, 2024

DURHAM, N.C. --(BUSINESS WIRE)--May 17, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination,...

Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

May 13, 2024

- Wholly owned programs on track for CTA and/or IND submissions - PBGENE-HBV for Hepatitis B virus in 2024 and PBGENE-PMM for primary mitochondrial myopathy in 2025 - First ARCUS in vivo gene editing program now open for enrollment in the United Kingdom through partnered OTC deficiency program;...

Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement

May 8, 2024

DURHAM, N.C. --(BUSINESS WIRE)--May 8, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL) (the “Company”), an advanced gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, elimination,...

Precision BioSciences to Report First Quarter Results on May 13, 2024

May 7, 2024

DURHAM, N.C. --(BUSINESS WIRE)--May 7, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision,...

Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE’s Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency

May 7, 2024

DURHAM, N.C. --(BUSINESS WIRE)--May 7, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, elimination, and excision,...

Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024

May 1, 2024

Data to be presented will highlight latest preclinical safety data for PBGENE-HBV in preparation for regulatory filings in 2024 DURHAM, N.C. --(BUSINESS WIRE)--May 1, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS ® platform...

Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics

April 16, 2024

- Productive collaboration advanced three programs and demonstrated proof of concept of ARCUS for gene excision and gene insertion - Precision exercised option to regain control of programs and intends to bring collaboration programs back to develop independently or with new partners - Precision’s...

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update

March 27, 2024

- Initiated final IND/CTA enabling studies for lead in vivo gene editing program PBGENE-HBV; expect to submit IND and/or CTA in 2024 - Completed licensing agreements to monetize divested CAR T assets with Imugene , TG Therapeutics and Caribou Biosciences including nearly $50 million in upfront and...

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024

March 20, 2024

DURHAM, N.C. --(BUSINESS WIRE)--Mar. 20, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision,...

Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy

March 19, 2024

- Data presented at Mitochondrial Medicine Therapeutic Development (MMTD) annual conference demonstrated ARCUS’ ability to efficiently eliminate mutant mitochondrial DNA without nuclear off-target editing - PBGENE-PMM shifted heteroplasmy by eliminating mutant m.3243 mitochondrial DNA (mtDNA) while...

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 19

Investors

Events & Presentations
Press Releases
Corporate Deck
Stock Information
Analyst Coverage
SEC Filings
Corporate Governance
Sustainability
Investor FAQs

Investor Tools

Print Page
Email Alerts
Contact IR
RSS Feeds

INVESTORS

Press Releases

Investors

Investor Tools

Contact Info

Learn More

Policies